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Abstract:  
 The androgen receptor (AR) is a key factor that regulates the behavior and fate of prostate cancer 
cells. The AR-regulated network is activated when AR binds enhancer elements and modulates specific 
enhancer-promoter looping. Kallikrein-related peptidase 3 (KLK3), which codes for prostate specific 
antigen (PSA) is a well-known AR-regulated gene and its upstream enhancers produce bidirectional 
enhancer RNAs (eRNAs), termed KLK3e. Here, we demonstrate that KLK3e facilitates the spatial 
interaction of the KLK3 enhancer and the KLK2 promoter and enhances long-distance KLK2 
transcriptional activation. KLK3e carries the core enhancer element derived from the androgen response 
element III (ARE III) which is required for the interaction of AR and Mediator 1 (Med1). Furthermore, 
we show that KLK3e processes RNA-dependent enhancer activity depending on the integrity of core 
enhancer elements. The transcription of KLK3e was detectable and its expression is significantly 
correlated with KLK3 (R
2
=0.6213, p<5x10
-11
) and KLK2 (R
2
=0.5893, p<5x10
-10
) in human prostate 
tissues. Interestingly, RNAi silencing of KLK3e resulted in a modest negative effect on prostate cancer 
cell proliferation. Accordingly, we report that an androgen-induced eRNA scaffolds the AR-associated 
protein complex that modulates chromosomal architecture and selectively enhances AR-dependent gene 
expression.   
 
Significance Statement: 
We report that eRNAs, a class of long noncoding RNAs (lncRNAs), participate in the AR-
dependent looping complex that enhances spatial communication of distal enhancers and target 
promoters, leading to transcriptional activation events. Furthermore, our data show that KLK3 eRNA 
(KLK3e) selectively enhances the gene expression of AR-regulated genes, and provide evidence for a 
positive regulatory loop in which AR-dependent transcription is modulated by an intermediate eRNA. 
These findings may translate into improved RNA-based therapy (eRNA suppression) to enhance the 
durability of androgen deprivation therapy (ADT) and prediction the efficacy of ADT by measuring the 
enhancer-derived activity (eRNA expression) in prostate tumors. 
 
Introduction:  
Androgens and the androgen receptor (AR) play pivotal roles not only in the development of the 
normal prostate gland but also in the growth and progression of prostate cancer (PCa) (1-4). Androgens 
exert their biological and physiological effects through activating AR transcriptional activity. AR, a 
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transcription factor, recruits ligand-dependent transcriptional machinery that activates a tissue-specific 
transcriptional program involved in development and differentiation (4-6). In PCa cells, AR occupies 
numerous gene loci to activate transcripts mediating critical cellular activities, such as energy and 
metabolism (5). AR activation and reactivation are essential for PCa development and tumor recurrence 
(7).  
One unanticipated observation that emerged from multiple global studies of RNA Polymerase II 
(Pol II) occupancy was that Pol II binds to a large number of intergenic AR-bound enhancers marked by 
histone H3 lysine 4 mono-methylation (H3K4me1) and lysine 27 acetylation (H3K27ac) and produces 
enhancer-derived long non-coding RNAs (eRNAs) (8-11). While eRNAs are bidirectional and non-
polyadenylated, their induction correlates with the induction of adjacent exon-coding genes (9). The 
activity of eRNAs was shown to augment the expression of not only neighboring but also intra-
chromosomally distant genes to convey enhancer-dependent transcription (12, 13). Recently, the 5’-
GRO-seq data have revealed that sequence-specific transcription factors and eRNA transcripts are 
required for transfer of full enhancer activity to a target promoter (14). Moreover, eRNAs have been 
shown to configure a chromatin state that facilitate transcription factors binding on the target promoters 
at defined genomic loci (15).  
Mechanistically, eRNAs have been shown to associate with the cohesin complex at estrogen 
receptor binding sites (ERBSs) and contribute to gene activation by stabilizing estrogen receptor- (ER-
)/eRNA-induced enhancer-promoter looping (16, 17). In addition, ncRNA-activating (ncRNA-a), a 
class of enhancer-like RNAs, has been shown to interact with the Mediator complex that enhances 
transcription in a cis-mediated mechanism (18), highlighting an RNA-dependent functional effect. 
Therefore, we hypothesized that eRNAs facilitates spatial communication of enhancers and promoters, 
thereby enhancing transcriptional activation events. Here, we report that the Kallikrein-related peptidase 
3 (KLK3) enhancer, one of the strongest AR-bound enhancers in prostate cancer cells, produces KLK3 
eRNA (KLK3e) which impacts androgen-induced gene activation. This work reveals that KLK3e 
selectively enhances AR-regulated gene expression through its collaboration with the AR-dependent 
looping complex. Thus, our findings provide evidence for a positive regulatory loop in which the AR-
regulated network is modulated by an intermediate eRNA.  
 
Results:    
The KLK3 enhancer produces enhancer RNA (KLK3e) 
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We compiled recently established genomic data sets (19) and showed that the KLK3 enhancer, 
also defined as the androgen response element III (ARE III) (20) was marked by AR, H3K27ac, and 
H3K4me1, implying that this region is transcriptionally active (Fig. 1A). In fact, the transcription of 
KLK3 eRNA (KLK3e) was demonstrated by GRO-seq data (10) and confirmed by our reverse 
transcription quantitative polymerase chain reaction (RT-qPCR) analyses in androgen-dependent 
LNCaP, VCaP and androgen-independent LNCaP-abl cells (21) (Fig. 1B, S1A, S1B). The expression of 
KLK3e was induced within the first hour of dihydrotestosterone (DHT) exposure and its expression 
level gradually increased in a time-dependent manner, resembling the expression of mature KLK3 in 
both LNCaP and VCaP cells; in contrast, while transcription at the KLK3 locus remains active in 
androgen-independent LNCaP-abl, androgens (DHT) did not stimulate their mRNA expression to a 
comparable magnitude as those in parental LNCaP cells (Fig. S1B). Next, we investigated the impact of 
AR antagonist, bicalutamide on the expression of KLK3e. The expression of KLK3e and KLK3 was 
induced upon DHT stimulation and blocked by bicalutamide (Fig. S1C), revealing that ligand-dependent 
eRNA synthesis takes place in association with target mRNA transcription. Taken together, our findings 
are consistent with the previous report that there is a high correlation of activity-dependent induction 
between eRNAs and adjacent coding mRNAs (9).   
Although multiple studies have identified different eRNA species from mammalian enhancers, 
the precise mapping of eRNAs has not been described. Since eRNAs produced from these intergenic 
enhancers are low at steady state (9) and estimated at fewer than 100 copies per cell (17), we enriched 
cellular RNAs by depleting ribosomal RNAs (rRNAs) prior to reverse transcription (RT). PCR primer 
sets against the antisense (AS1-AS4) and sense (S1-S7) of KLK3e were designed based on the GRO-seq 
and genomic data sets (10, 19). As shown in Fig. 1C, the transcription of bidirectional KLK3e as was 
captured; whereas, no robust DHT-induced transcription was detectable beyond AS4 and S7. We 
performed primer-extension PCR assay to connect shorter fragments (Fig. S1D) and further showed 
PCR products for the antisense (2230bp) and sense (2170bp) of KLK3e (Fig. 1C and cDNA sequences 
available in SI). To distinguish whether the eRNA at KLK3 enhancer are polyadenylated or not, we 
performed reverse transcription using random hexamer primers and 3’ RACE (Poly-T) adapter from the 
same RNA materials. As shown in S1E, the expression of AS4 and S7 was substantially induced by 
DHT treatment, suggesting that the poly-A tail was added to the 3’-end of antisense and sense KLK3e. 
In contrast, S1 showed less DHT-stimulated expression in the Poly-T priming as compared to random 
hexamer primed cDNA. These data suggest that this locus produces a mixture of RNA species; some of 
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them are polyadenylated while others may be actively undergoing synthesis of polyadenylation, but we 
cannot totally exclude the existence of those species without poly-A tails. To detect the size of the 
mature eRNA at this loci, we customized double DIG-labeled probes using Locked Nucleic Acids 
(LNA™) (Exiqon). Northern analysis revealed that a major form (~2.5kb) and a minor form (~1.7kb) of 
sense KLK3e were produced upon DHT induction; whereas no signal was detected at the antisense 
strand (Fig. S1F), suggesting that the expression of antisense strand may be lower than the levels that 
can be detected by the LNA probe. (Fig. S1F). Collectively, this suggests that the sense strand (S1-S7) 
KLK3e, a ~2.2 kb transcript, is polyadenylated and yields a ~2.5 kb transcript shown in Northern 
analysis. Although the antisense KLK3e can be polyadenylated and detected by qPCR, its expression 
may be substantially lower than the sense strand and cannot be detected by Northern analysis under the 
same experimental settings, indicating that the sense strand KLK3e is the dominate species.  
 
The regulatory function of KLK3e on the Kallikrein Locus 
To investigate the potential function of eRNAs in transcriptional regulation, short interfering 
RNAs (siRNAs) targeting KLK3e (siKLK3e) were designed on the basis of KLK3e mapping. Results 
obtained from distinct sets of siRNAs against the sense strand of KLK3e showed that siKLK3e 
specifically targeted sense KLK3e and significantly impeded DHT-induced KLK3 expression in both 
LNCaP and VCaP cells but had a minimal impact on LNCaP-abl cells (Fig. 2B and S2A, B, C, D, and 
E), consistent with the notion that ligand-activated eRNAs are important for nearby gene activation (13, 
17). Considering that KLK15, 2, and 4 were adjacent to KLK3 and androgen-responsive (Fig. 2A), we 
examined whether KLK3e impacted transcription of these KLKs. Interestingly, knocking down of sense 
KLK3e significantly inhibited the expression of KLK2; whereas, other KLKs remained unchanged (Fig. 
2B). We also investigated the effect of antisense KLK3e on the regulation of target gene expression. 
RNAi silencing of the antisense of KLK3e showed a marginal inhibitory effect on KLK3 and KLK2 
gene expression (Fig. S2F). Despite the presence of bidirectional KLK3e transcription, data from siRNA 
to KLK3e and Northern analysis showed that the sense strand of KLK3e is the dominant transcript with 
functional effects on the expression of KLK3 and distant KLK2. Thus, we chose the sense KLK3e and 
continued to study its RNA-dependent enhancer activity. 
Since the induction of eRNA is strongly correlated with the enhancer looping to target gene 
promoters (13, 16, 17), it is possible that the KLK3 enhancer element is able to interact with the KLK2 
promoter. To address this, we utilized the chromosome conformation capture (3C) assay to study the 
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spatial interaction of the KLK3/2 loci. It should be noted that the KLK2 promoter contains an ARE I 
which shares over 80% sequence homology with the ARE I in the KLK3 promoter (20). Indeed, DHT 
induces KLK2 transcription and the interaction between the anchor and fragment D and E by 2~3 fold 
(Fig. 2C). Amplified PCR of anchor-fragment D (105bp) and anchor-fragment E (115bp) was confirmed 
by DNA sequencing (Fig. S2G and H), suggesting that the KLK3 enhancer interacts with the KLK2 
promoter to mediate distal KLK2 gene activation. 
To study the mechanism of KLK3e-mediated transcriptional events, we looked for KLK3e 
interacting partners by asking whether KLK3e interacts with AR, since KLK3e carries the core enhancer 
element. We conducted AR-directed RNA immunoprecipitation (RIP) coupled with qPCR using primer 
sets targeting the core enhancer element at 5’end (S1), middle segment (S4) and 3’ end (S7) of the sense 
KLK3e (Fig. 1C). Our results show a specific DHT-induced interaction between AR and S1 (Fig. S2I), 
suggesting that AR relies on the core enhancer element of KLK3e. Since Med1 has been shown to 
directly interact with AR and is involved in the chromosomal interaction of enhancer-promoter looping 
(22, 23), we next asked whether Med1 participates in the observed eRNA functions. RIP analysis 
revealed a strong androgen-stimulated interaction of S1 and Med1 (Fig. S2J), comparable to the 
interaction of KLK3e and AR. Conversely, the antisense KLK3e (AS1) exhibited modest interaction 
with AR and Med1 (Fig. S2K), implying that the enhancer function of these two KLK3e species is 
determined by the levels of interaction with the AR-Med1 complex.  
To investigate the potential role of KLK3e in the KLK3/2 loci, we next used 3C-qPCR to assess 
the interaction of the anchor-fragment D/E regions in KLK3e depleted cells. Silencing of KLK3e 
impaired KLK2 gene expression and the interaction of the KLK2 promoter and the KLK3 enhancer (Fig. 
2D). Suppression of Med1 also substantially reduced the interaction of the KLK3/2 loci (Fig. 2D, S2L), 
supporting a pivotal role of Med1 in mediating this long range chromatin looping (18, 22). Hence, our 
results demonstrate that both KLK3e and Med1 are involved in maintaining the spatial interaction 
between an enhancer and a target promoter.  
 
The KLK3e/AR/Med1 ribonucleoprotein complex transcriptionally regulates target promoters    
To ensure that the endogenous KLK3e plays a functional role on its target promoters, we 
performed chromatin immunoprecipitation (ChIP) using antibodies against AR and activated RNA 
Polymerase II (Pol II S5p) in KLK3e depleted cells. These analyses demonstrated that depletion of 
KLK3e inhibited AR binding and Pol II activation at the KLK2 promoter, consistent with the reduction 
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of gene expression of KLK2 (Fig. 3A). Next, we examined the regulatory effect of Med1 on the target 
promoters. As expected, knockdown of Med1 significantly reduced AR occupancy and Pol II activation 
at the KLK2 promoter (Fig. 3B). Whether KLK3e collaborates with Med1 and functionally affects 
transcription of the KLK2 promoter is unclear. Depletion KLK3e resulted in decrease of Med1 binding 
to the promoters of KLK2 (Fig. 3C). In addition, the effect of siKLK3e and siMed1 on the gene 
expression of KLK2 and Med1 was shown in Fig. S3A. Altogether our data suggest that KLK3e 
cooperates with Med1 to enhance KLK2 gene expression. It should be noted that the actions of AR, 
Med1 and Pol II at the KLK3 promoter were comparable to those at the KLK2 promoter (Fig.S3B, C 
and D), implying that the regulatory function of KLK3e at the KLK3/2 promoters may act through the 
same AR-dependent ribonucleoprotein complex.  
Interestingly, silencing of KLK3e did not affect the action of AR and Pol II on the KLK3 
enhancer (Fig S3E), suggesting that the biogenesis of KLK3e takes place after ligand-activated AR was 
recruited to the enhancer. While depletion of Med1 blocked AR binding and Pol II activation on the 
KLK3 enhancer, the expression of KLK3e was not significantly affected, implying that residual Med1-
associated module may be sufficient for KLK3e production (Fig.S3F). Collectively, our data show the 
mechanism by which KLK3e forms a functional complex with AR and Med1 to promote transcription, 
supporting the findings that transfer of full enhancer activity to a target promoter depends on enhancer-
bound transcription factors and enhancer-derived RNA transcripts (14). 
 
The core enhancer element renders KLK3e RNA-dependent enhancer activity.   
To validate the enhancer function of KLK3e, we utilized a luciferase reporter assay to 
quantitatively measure AR transcriptional activity. While inclusion of KLK3e (S1-S7) or flipped (S7-S1) 
sequences markedly increased KLK2 promoter activity by 4~5 fold, this effect was abolished when 
ARE III sequences were deleted (S2-S7) (Fig. 4A), confirming the importance of the enhancer integrity 
and their orientational independency (17, 24).  
 The expression of the KLK3e from the luciferase reporter was validated by RT-PCR (Figure 
S4A), indicating that AREs have the capacity to produce eRNAs. We next asked whether the KLK3e 
transcript alone is adequate for this transcriptional enhancement. For this purpose, we performed a co-
transfection study based on reporters together with CMV-driven sense KLK3e constructs. As shown, the 
full-length (S1-S7) and flipped (S7-S1) KLK3e increased luciferase expression by 2~2.5 fold; whereas, 
ARE deletion (S2-S7) failed to enhance promoter activity (Fig. 4B). Furthermore, antisense KLK3e 
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(AS1-AS4) was unable to induce luciferase expression as sense KLK3e (S1-S7) did (Fig. S4B and C), 
again arguing that the sense KLK3e is the functional lncRNA rather than the antisense strand. To 
examine whether AR is required for the action of KLK3e, we conducted experiments in AR-negative 
COS-7 cells and confirmed that the activity of KLK3e depends on the availability of ligand-activated 
AR (Fig. S4D and E). Altogether, these data show that the core enhancer elements are essential for the 
enhancer activity of KLK3e and that ectopic KLK3e induces the promoter activity on a luciferase 
reporter, implying a trans-regulatory activation mediated by KLK3e.  
As a complementary approach, we also addressed whether the observed luciferase expression is 
mediated through endogenous KLK3e. RNAi silencing of KLK3e significantly reduced luciferase 
activity in the reporters with or without KLK3e insertion (Fig. 4C, left), showing that KLK3e is required 
for the enhancement of DHT-induced activation. When KLK3e was ectopically expressed, it restored 
the luciferase expression inhibited by KLK3e suppression (Fig. S4F). Most importantly, the luciferase 
activity in the reporter with KLK3e insertion was reduced by ~50% in Med1 depleted cells (Fig. 4C, 
right), suggesting that Med1 facilitates KLK3e-dependent transcription. Notably, ncRNA-a has been 
shown to mediate long-range transcriptional activation through its association with the Med1 complex 
(18). In summary, our results strongly suggest that KLK3e forms a functional complex with AR and 
Med1 which facilitates the association of AR-bound enhancers with promoters of target genes, resulting 
in transcriptional activation.  
 
KLK3 eRNA selectively enhances AR-regulated gene expression  
To explore the potential effect of KLK3e beyond the KLK locus, we measured the expression of 
canonical androgen-regulated genes in KLK3e depleted cells. Suppression of KLK3e decreased the 
expression of NKX3.1, FKBP5 and PLZF; whereas, the expression of TMPRSS2, PDE9A and 
GUCY1A3 was not affected (Fig. 5A). Additionally, we observed a comparable KLK3e-mediated 
inhibition of NXK3.1 gene expression in VCaP cells (Fig. S2D). Moreover, we showed the expression 
eRNAs at upstream of NKX3.1, FKBP5, PLZF was induced by DHT but not affected by KLK3e siRNA 
knockdown (Fig. S5A), suggesting that the KLK3e siRNA does not interfere the transcription of eRNAs 
found at the enhancers of NKX3.1, FKBP5 and PLZF. Although eRNA-mediated trans effects are likely 
to be relatively infrequent or quantitatively small (17), our data show that KLK3e selectively regulates 
the expression of AR-regulated genes which do not reside on the same chromosome, implying a trans-
regulatory function of KLK3e on AR-dependent gene expression.  
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We further assessed the regulatory role of KLK3e and Med1 on the promoter of NKX3.1 and 
TMPRSS2 to mechanistically validate our above findings in the KLK loci. While depletion of KLK3e 
significantly reduced the enrichment of AR and Pol II S5p at the NKX3.1 promoter (Fig. S5B, upper 
panel), the action of these factors at the TMPRSS2 promoter was unaffected (Fig. S5B, lower panel). In 
contrast, Med1 knockdown considerably blocked both AR occupancy and Pol II activity at both the 
NKX3.1 and TMPRSS2 promoters (Fig. S5C). These results demonstrate that KLK3e selectively 
enhances gene expression, while Med1 has a more general effect on the regulation of AR-dependent 
transcription. Most importantly, KLK3e depletion reduced Med1 recruitment to the promoter of 
NKX3.1, not TMPRSS2 (Fig. S5D and E), revealing that this eRNA/AR/Med1 complex may possess a 
degree of specificity in the AR-dependent transcriptional machinery. Furthermore, we evaluated the 
gene expression from the normal human prostate gland (n=4), primary (n=11) and metastatic (n=32) 
human prostate tumors (25) and showed that the correlation (R
2
) of KLK3e (S1) with KLK3, KLK2, 
NKX3.1 and TMPRSS2 was 0.6213 (p<5x10
-11
), 0.5893 (p<5x10
-10
), 0.4624 (p<2x10
-7
) and 0.3787 
(p<5x10
-6
), respectively. In addition, the expression the KLK3 and KLK2 was the most correlated 
(R
2
=0.8361, p<3x10
-16
) (Fig. 5B and S5F). Collectively, these in vivo data indicate that the transcription 
of KLK3e was detectable and its presence correlates with KLK3/2 gene expression. We noted less of a 
correlation between KLK3e expression and those genes in trans, and the correlation was stronger with 
NKX3.1 than TMPRSS2, consistent with our in vitro data, although these data do not prove a direct 
effect in vivo of KLK3e on the transcription of these genes. Next, we investigated the biological effect 
of KLK3e siRNA on LNCaP cells and showed that KLK3e depletion significantly compromised cell 
growth in the presence and absence of exogenous androgens (Fig. 5C). While this negative effect is 
modest, we postulate that suppression of multiple eRNAs produced from distinct enhancer elements may 
synergetically block AR transcriptional program. Thus, substantial efforts are needed to fully 
characterize the transcriptional and biological functions of other significant androgen-induced eRNAs in 
the future. 
 
Discussion 
We demonstrate that bidirectional KLK3e was produced from one of the strongest AR-bound 
enhancers (ARE III) and its expression pattern resemble KLK3 in prostate cancer cell lines (Figure 1, 
S1), in agreement with the previous report that a high correlation of activity-dependent induction exists 
between eRNAs and adjacent coding mRNAs (9). Suppression of KLK3e exclusively reduces gene 
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expression of KLK3 and KLK2, not other KLK family members and that KLK3e facilitates the 
assembly of the transcriptional apparatus at the promoters during gene activation events. This classifies 
KLK3e as a family of functional lncRNA involved in enhancing long distance gene transcription.  
Whether eRNAs function as molecular bridges that mediate spatial interactions of distal 
enhancers and target promoters, or directly configure a chromatin state that facilitate transcription factor 
binding at the target promoters is unclear. Recently, chromatin isolation by RNA purification (ChIRP) 
coupled with deep sequencing was deployed to interrogate the nature of RNA and DNA interaction in a 
genome wide scale (26). Rosenfeld and colleagues used this methodology to identify potential sites 
where estrogen-induced FOXC1 eRNA localizes in the genome (17). While FOXC1 eRNA is 
specifically enriched in a small fraction of genomic loci, there were no known estrogen-regulated genes 
found adjacent to these RNA/DNA binding sites (17), implying that the functional effect of eRNAs on 
target genes may not completely rely on nucleotide base pairing. In this report, we demonstrate that 
KLK3e mediates chromosomal looping of KLK3/2 loci and confirmed in a heterologous reporter assay 
that KLK3e cooperates with AR and Med1 to enhance KLK2 promoter activity through that the core 
enhancer element (ARE III). The state of KLK3e and KLK3/2 was further validated in human prostate 
tissues (n=47) and showed that the expression of KLK3e significantly correlates with KLK3 (R
2
=0.6213, 
p<5x10-11) and KLK2 (R
2
=0.5893, p<5x10-10), implying that KLK3e may coordinate the transcription 
of KLK3/2 (Fig. 5B). However, we do not completely understand how KLK-associated eRNAs are 
regulated in castration resistant prostate cancer (CRPC), although it is well-accepted that the AR-
mediated transcriptional program remains active. This observation can be explained by the activity of 
other nuclear receptors, since the core sequence of ARE can be also be recognized by glucocorticoid 
receptor (GR), progesterone receptor (PR), and mineralocorticoid receptor (MR) (27). More importantly, 
it has been shown that AR inhibition resulted in GR upregulation in a subset of prostate cancer cells 
supporting a mechanism of bypassing AR blockade via an alternative nuclear receptor in CRPC (28). 
Thus, it is possible that GR, PR or MR may mediate the expression of KLK3e, KLK3 and KLK2, 
attributing to adaptive or compensatory effects generated during CRPC development.  
In view of the regulatory potential of lncRNAs on gene regulation in trans (29-31), eRNAs may 
be part of co-activator complexes and regulatory factors that participate in the transcriptional regulatory 
network. Although the entire circuitry of AR-dependent genes is unlikely controlled by a single eRNA, 
presumably, there are more androgen-induced eRNAs, and there could be redundancy in their enhancer 
activity. It is conceivable that multiple eRNAs produced from distinct enhancer elements tether with 
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their own transcriptional modules that operate simultaneously to initiate an accurate and a rapid 
transcriptional program. Therefore, we propose that an eRNA may function as a scaffold that guides an 
AR-associated protein complex to target chromatin and selectively enhances DHT-stimulated 
transcription either intra-chromosomally (cis activity) or inter-chromosomally (trans activity). This 
positive regulatory loop may provide new insight into RNA-dependent functional effects on the 
regulation of lineage- or tissue-specific gene expression.  
While androgen-deprivation therapy (ADT) is designed to block the androgen signaling pathway 
and is the standard treatment for advanced prostate cancer, this study may help us to understand how 
androgen ADT influences the activity of AR-bound enhancers through altered expression of eRNAs. In 
addition, the differential eRNA expression patterns observed may be predicative markers of ADT 
efficacy for individual prostate cancer patients. More importantly, eRNAs may represent new targets 
that when suppressed may improve the therapeutic durability of ADT.  
 
Experimental Procedures:  
 
Chromatin Immunoprecipitation (ChIP) assay 
ChIP experiments were performed as previously described (19) with some modifications. Briefly,  
10 million cells were used per IP. Cells were fixed with 1% formaldehyde solution. DNA was sonicated 
and subjected into immunoprecipitated with antibodies against androgen receptor (N-20X, Santa Cruz 
biotechnology), Med1/TRAP220 (A300-793A, Bethyl Laboratories), RNA Polymerase II (p-Ser5) 
(ab5131, abcam), or nonspecific IgG. DNA was purified and analyzed by qPCR. The primers for qPCR 
are provided in the Supplemental Information 
 
RNA Immunoprecipitation (RIP) assay 
RIP experiments were performed as described previously with some modification (31). Briefly, 10 
million cells were used per IP. Cells were fixed in 0.3 % formaldehyde solution. Total chromatin and 
RNAs were sonicated and subjected into immunoprecipitation with the same AR and Med1 antibodies 
used in ChIP experiments. Immunoprecipitated RNAs were isolated using TRIzol LS reagent, followed 
by cDNA synthesis. The primers for qPCR are provided in the Supplemental Information. 
 
Chromosome Conformation capture (3C) assay 
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3C assay was performed as previously described with some modifications (32). After DHT (10nM) 
treatment, LNCaP cells were fixed with 1% formaldehyde. Cell pellets were lysed and resuspended in 
restriction buffer for BstY1 and 0.1% SDS for 10 min at 65
0
C. Trion X-100 was added to a final 
concentration of 1.8% followed by overnight digestion of BstY1 (1500 U per 10
7
 cells) at 37°C. DNA 
ligation was performed for 4 days at 16°C. The ligated samples were reverse-crosslinked with proteinase 
K at 65
0
C overnight, followed by Phenol/Chloroform extraction, EtOH precipitation. The primers for 
qPCR are provided in the Supplemental Information. 
 
Additional experimental procedures and methods are listed in the Supplementary Information. 
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Figure Legends: 
Figure 1. The KLK3 enhancer produces long non-coding RNAs 
 
(A) The chromatin status in the vicinity of KLK3. ChIP-seq data sets of AR, H3K27ac, and H3K4me1 
(19).  
(B) RT-qPCR analyses of expression of antisense KLK3 eRNA (red bar), sense KLK3 eRNA (green 
bar), and mature KLK3 (blue bar) upon DHT (10nM) treatment in a time-dependent manner in LNCaP 
cells.   
(C) Top panel: A diagram of functional ARE positions that are relative to the KLK3 transcription 
starting site (TSS) adapted from (20);  
Bottom panel: RT-qPCR analyses of the expression of segments of KLK3e with DHT (10nM) treatment 
in LNCaP cells. The regions of LNA probes against the antisense and sense KLK3e were as indicated. 
Primer sets for qPCR were designed to specifically target either antisense (primers AS1-AS4) or sense 
strand (primer S1-S7) of KLK3e as showed. The right electrophoresis images show the PCR products of 
antisense (2230 bp) and sense (2170 bp) KLK3e.  
All data analyzed by RT-qPCR were normalized to the expression level in vehicle (-). Data were shown 
as mean ± S.D. (n≥3). 
 
Figure 2. The regulatory function of KLK3e on the KLK locus 
 
(A) A heatmap of the KLK transcripts upon 4hr and 16 hr of DHT exposure in LNCaP cells (21). Genes 
are listed as their order in the kallikrein loci from centromere (top) to telomere (bottom).  
(B) Top panel: Schematic drawing indicates the relative position of AR-regulated KLK genes and 
KLK3e on the chromosome 19;  
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Bottom panel: LNCaP cells were treated with vehicle (-) or DHT (10nM) and 50 nM of non-silencing 
control (siCtrl) or KLK3e siRNA (siKLK3e); lower case ‘e’ denoted as eRNA. Efficacy and effects of 
KLK3e depletion on KLK genes were assessed by RT-qPCR.  
(C) Top panel: Schematic graph shows the KLK3/2 gene loci;  
Bottom panel: LNCaP cells were treated with vehicle or DHT for 4 hrs. KLK2 mRNA expression was 
accessed by RT-qPCR (Insert). The relative cross-linking frequency between the anchor region (ARE III) 
and distal fragments (shaded bars) was determined by qPCR and normalized to the control region 
(Fragment A).  
(D) The relative cross-linking frequency between the anchor region-D and -E region was determined by 
qPCR and normalized to the A region.  
All data analyzed by RT-qPCR or qPCR were normalized to the expression level in vehicle and shown 
as mean ± S.D. (n≥3) and * p<0.05. 
 
Figure 3. The KLK3e/AR/Med1 ribonucleoprotein complex transcriptionally regulates target 
promoters 
 
Chromatin immunoprecipitation (ChIP) of AR or Med1 or activated Pol II (S5p) was performed in 
KLK3e or Med1 depleted LNCaP cells with or without DHT (10nM) for 2 or 8 hrs.  
(A, B, C) qPCR was conducted to measure the action of AR, Pol II (S5p) and Med1 at the KLK2 
promoter. Data were shown as mean ± S.D. (n≥3) and * p<0.05.  
 
Figure 4. The core enhancer element renders KLK3e RNA-dependent enhancer activity 
 
(A)Top panel: Schematic representation shows the insertion in KLK2 promoter driven luciferase 
reporter.  
Bottom panel: Reporter assays analyses were performed with or without insertion of full-length (S1-S7), 
flipped (S7-S1) and ARE deleted (S2-S7) of sense KLK3e.  
(B) Reporter analysis of co-transfecting the reporter with independent overexpressing vector as indicated.   
(C) The effects of siKLK3e (left) or siMed1 (right) on the KLK2 promoter-driven Luciferase activity.  
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Luciferase activity was measured in the presence of DHT (10nM) for 24 hrs. All data shown are mean 
±S.D. of at least three independent experiments. * p<0.05; firefly luciferase/ Renilla luciferase (FL/RL). 
 
Figure 5. KLK3e selectively enhances AR-regulated gene expression   
 
(A) LNCaP cells were treated with vehicle or DHT (10nM) and/or siCtrl or siKLK3e. The effect of 
siKLK3e on AR-regulated gene expression was determined by RT-qPCR.  
(B) Correlation between KLK3e (S1) and target gene expression in vivo. All data were normalized for 
GAPDH by the differences in threshold cycles (∆CT) from the normal human prostate gland (n=4), 
primary (n=11) and metastatic (n=32) prostate tumors (25).  
(C) LNCaP cells were cultured in 5% charcoal/dextran treated FBS (C-FBS) medium, followed by 
siRNA knockdown of scrambled control (siCtrl) or KLK3e (siKLK3e) with ethanol (veh) or DHT 
(10nM) treatment. Cell growth was measured by WST1 assay. Data represent mean ± S.D. (n≥3) and * 
p<0.05.  
(D) A proposed model for functional activities of the eRNA/AR/Med1 complex in DHT-induced cis 
(solid line) and potential trans (dish line) gene activation events. 
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Supplemental Information: 
 
Figure S1. The KLK3 enhancer produces long non-coding RNAs, related to Figure 1. 
(A, B)  VCaP and LNCaP-abl cells were treated with DHT (10nM) in a time dependent manner. The 
expression of antisense (red bar), sense (green bar), or mature KLK3 (blue bar) was determined by RT-
qPCR.  
(C) LNCaP cells were treated with or without 10 nM of DHT and 10M of bicalutamide (bic). The 
expression of KLK3e and KLK3 was measure by RT-qPCR. 
(D) Electrophoresis images show that the PCR products from fragments of antisense and sense KLK3e 
upon DHT (10nM) stimulation for 24 hr. 
(E) Reverse transcription was performed using random hexamer primers and 3’ RACE (Poly-T) 
adapter from the same RNA materials isolated from LNCaP cells treated with or without DHT (10 nM). 
The expression of KLK3e and KLK3 was measure by RT-qPCR. 
(F) RNA was isolated and purified from LNCaP cells treated without (-) or with (+) DHT. 2 g or 40g 
of total RNA was subjected to electrophoresis, followed by hybridization using the LNA probes against 
KLK3, actin, antisense and sense KLK3e whose targeting regions are shown in Fig. C. 
All data analyzed by RT-qPCR were normalized to individual expression in the absence of DHT 
exposure. Data represent mean ± S.D. (n≥3) and * p<0.05. 
Figure S2. The regulatory function of KLK3e on the KLK locus, related to Figure 2. 
Suppression of antisense (AS) and sense (S) KLK3e using distinct siRNA sets (1 construct targeting AS; 
whereas 2 constructs targeting S7 and 1 construct targeting S1) in LNCaP cells.  
(A, B, E) RT-qPCR was used to determine the effect of KLK3e siRNAs on target mRNA expression. 
Transfection of siKLK3 and/or pcDNA/KLK3 in an AR-negative COS-7 cells.  
(C) The gel image shows the PCR product of KLK3e (S1-S7) that is diminished in the presence of 
siKLK3e; RT, reverse transcription.  
(D, E) Efficacy and effects of siKLK3e on KLK3e and AR-regulated genes in VCaP and LNCaP-abl 
cells were assessed by RT-qPCR.  
(F) Efficacy and effects of siRNA against the antisense or sense KLK3e on KLK3e and AR-regulated 
genes in LNCaP cells were assessed by RT-qPCR. 
(G) Electrophoresis images show the PCR products of anchor-fragment D (105bp) and anchor-fragment 
E (115bp) with or without DNA ligation.  
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(H) DNA sequencing results from the PCR products of the KLK3 enhancer and KLK2 promoter using 
the primer sets of anchor-fragment D and -fragment E.  
(I, J) Fragments of sense or (K) antisense KLK3e interact with the AR and Med1. RNA 
immunoprecipitation (RIP) of AR or MED1 was performed using LNCaP cells treated with vehicle or 
DHT (10nM) for 4 hrs.  
(L) The effect and efficacy of siKLK3e or siMed1 with or without DHT on KLK2 gene expression was 
measured by RT-qPCR.   
All data analyzed by RT-qPCR or qPCR were normalized to the expression level in vehicle. Data were 
shown as mean ± S.D. (n≥3) and * p<0.05. 
 
Figure S3. The KLK3e/AR/Med1 ribonucleoprotein complex transcriptionally regulates target 
promoters, related to Figure 3. 
qPCR was conducted to measure the activity on the (B, C, D) KLK3 promoter and (E, F) KLK3 
enhancer. Also accessed was the mRNA expression of (A) KLK2, and Med1 as well as (B, C, E, F) 
KLK3e and KLK3 by RT-qPCR analysis. Data represent mean ± S.D. (n≥3) and * p<0.05. 
 
Figure S4. KLK3e harbors sequence-specific enhancer activity, related to Figure 4. 
LNCaP cells were transfected with expression plasmids as indicated.  (A, C) The gel image shows PCR 
product of sense (S7) or antisense (AS4) KLK3e.Co-transfection of constructed reporters and/or 
overexpressing plasmids as indicated in (B) LNCaP and (D, E, F) COS-7 cells were treated with DHT 
for 24 hrs for Luc reporter analysis. All data shown are mean ±S.D. of three or more independent 
experiments. * p<0.05; firefly luciferase/Renilla luciferase (FL/RL). 
 
Figure S5. KLK3e selectively regulates the promoter activity of target gene, related 
 to Figure 5.   
(A) The chromatin status at the upstream enhancers of FKBP5, NKX3.1 and PLZF. ChIP-seq data sets 
of AR, H3K27ac, and H3K4me1 (28). RT-qPCR analyses of the expression of eRNAs with or without 
KLK3e silencing and/or DHT (10nM) treatment in LNCaP cells.   
Chromatin immunoprecipitation (ChIP) of AR or Med1 or activated Pol II (S5p) was performed in 
KLK3e or Med1 depleted LNCaP cells with or without DHT (10nM) for 2 or 8 hrs.  
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ChIP of AR or Med1 or activated Pol II (S5p) was performed using LNCaP cells transfected with (B, D, 
E) siKLK3e or (C) siMed and treated with or without DHT (10nM) for 2 or 8 hrs. qPCR analysis was 
used to access the promoter activity of NKX3.1 and TMPRSS2. mRNA expression levels of NKX3.1 
versus TMPRSS2 in KLK3e and Med1 depleted LNCaP cells were determined by RT-qPCR.   
(F) Correlation between KLK3 and KLK2 gene expression in vivo. All data were normalized for 
GAPDH by the differences in threshold cycles (∆CT) from the normal human prostate gland (n=4), 
primary (n=11) and metastatic (n=32) prostate tumors (33). 
All data shown are mean ±S.D. of three or more independent experiments, * p<0.05. 
 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES:  
 
Cell Culture and siRNA Transfection 
LNCaP cells were cultured in RPMI1640 medium with 10% FBS. VCaP and COS-7cells were cultured 
in DMEM medium with 10% FBS. Prior to androgen induction or transfection, cells were grown to 
50%–60% confluence in 5% charcoal/dextran treated FBS (C-FBS) medium for 3 days and then treated 
with 10 nM of DHT or siRNA (50nM). 
RNA, Isolation, Purification, and cDNA Synthesis 
Prostate cancer cells and human prostate tissue frozen sections (25) were harvested and resuspended in 
TRIzol (Invitrogen) and RNAs were extracted according to the manufacturer’s protocol. Total RNAs 
were purified by RNeasy Kit (QIAgene). Purified RNA from LNCaP cells was subsequently washed by 
RiboMinus Eukaryote Kit (Invitrogen). The ribosomal RNA depleted RNA fraction was subject to 
cDNA synthesis was performed using High Capacity cDNA Reverse Transcription Kit (Life Technology) 
or 3’RACE poly-T adaptor (Ambion).  
 
Reagents used for siRNA-Mediated Knockdown experiments 
siRNA sequences targeting the sense strand of KLK3e: 3’-end (S7) #1, 5’-gaggaugaguugaggauauuu-3’; 
#2, 5’-ggguuggcuuguuagguuauu-3’; 5’-end (S1): 5’-ggaacauauuguaucgauuuu-3’ and the antisense 
strand (siAS): 5’-gcaaaaggauacagaugaauu-3’. siRNA targeting Med1 and non-targeting siRNA were 
ON-TARGETplus Human MED1 siRNA and ON-TARGETplus Non-Targeting siRNA#1 from Thermo 
Scientific. Transfection of LNCaP and COS-7 cells was performed with Lipofectimane 2000 or 
Lipofectimane RNAiMax (Invitrogen) according to the manufacturer’s protocol. 
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Plasmid Constructs for Luciferase Assay  
Full-length (S1-S7), flipped (S7-S1), ARE deleted (S2-S7), and antisense (AS1-AS4) of KLK3e were 
subcloned into pcDNA3 (Invitrogen) using EcoRI and XbaI sites. pGL3-Basic (Promega) was digested 
with SacI and XhoI and KLK2 promoter (-407~+143) promoter was inserted into these sites. 
Additionally, TK promoter sequences from pRL-TK (Promega) were subcloned into pGL3/KLK2 
promoter using BglII and HindIII. Full length (S1-S7), flipped (S7-S1) and ARE deleted (S2-S7) KLK3e 
were inserted into downstream of SV40 late poly(A) signal of luciferase reporter. Luciferase 
experiments were conducted in 96-well white plates using Dual-Glo (Promega) according to the 
manufacturer’s protocol.  
 
Northern blot analysis 
Northern blot assay was performed using DIG Northern Starter Kit (Roche) with some modifications. 
Total RNA was isolated and purified from LNCaP treated with or without DHT (10 nM). 2g or 40g 
of RNA were subjected to electrophoresis, followed by hybridization using the 10 nM of LNA probes 
(Exiqon) against KLK3: /5DigN/tcaggaggctcatatcgtaga/3DigN/, actin (Exiqon), sense  KLK3e: 
/5DigN/atgctggatgatgagtggatga/3DigN/ and antisense  KLK3e: /5DigN/agtgacctaacatctctgtga/3DigN/. 
 
Cell Proliferation assay 
Cell growth was examined using the WST1 assay (Roche) following the manufacturer’s protocol. 
Briefly, 3,000 LNCaP cells were grown in a 96-well-plate in the RPMI-1640 medium containing 5% C-
FBS. After 2-day incubation, cells were transfected with 50 nM of siRNAs to non-silencing control 
(siCtrl) or KLK3e (siKLK3e). After 24 hours of incubation, cells were treated with ethanol (Veh) or 
DHT (10nM). Then, the WST1 assay was performed after Day 0-6.  
 
Supplemental Information: 
sense and antisense KLK3e sequences: 
sense (S1-S7): 
TGGGACAACTTGCAAACCTGCTCAGCCTTTGTCTCTGATGAAGATATTATCTTCATGATCTT
GGATTGAAAACAGACCTACTCTGGAGGAACATATTGTATCGATTGTCCTTGACAGTAAACA
AATCTGTTGTAAGAGACATTATCTTTATTATCTAGGACAGTAAGCAAGCCTGGATCTGAGA
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GAGATATCATCTTGCAAGGATGCCTGCTTTACAAACATCCTTGAAACAACAATCCAGAAAA
AAAAAGGTGTTGCTGTCTTTGCTCAGAAGACACACAGATACGTGACAGAACCATGGAGAAT
TGCCTCCCAACACTGTTCAGCCAGAGCCTTCCACCCTTGTCTGCAGGACAGTCTCAACGTTC
CACCATTAAATACTTCTTCTGTCACATCCTGCTTATTTATGCCTAACCAAGGTTCTAGGTCCC
GATCGACTGTGTCTGGCAGCACTCCACTGCCAAACCCAGAATAAGGCAGCGCTCAGGATCC
CGAAGGGGCATGGCTGGGGATCAGAACTTCTGGGTTTGAGTGAGGAGTGGGTCCACCCTCT
TGAATTTCAAAGGAGGAAGAGGCTGGATGTGAAGGAACTGGGGGAGGGAAAGTGTCAGTT
CCGAACTCTTAGGTCAATGAGGGAGGAGACTGGTAAGGTCCCAGCTCCCGAGGTACTGATG
TGGGAATGGCCTAAGAATCTCATATCCTCAGGAAGAAGGTGCTGGAATCCTGAGGGGTAG
AGTTCTGGGTATATTTGTGGCTTAAGGCTCTTTGGCCCCTGAAGGGCAGAGGCTGGAACCA
TTAGGTCCAGGGTTTGGGGTGATAGTAATGGGATCTCTTGATTCCTCAAGAGTCTGAGGAT
CGAGGGTTGCCCATTCTTCCATCTTGCCACCTAATCCTTACTCCACTTGAGGGTATCACCAG
CCCTTCTAGCTCCATGAAGGTGCCCCTGGGCAAGCACAATCTGAGCATGAAAGATGCCCCA
GAGGCCTTGGGTGTCATCCACTCATCATCCAGCATCCACACTCTGAGGGTGTGGCCAGCAC
CATGACGTCATGTTGCTGTGACTATCCCTGCAGCGTGCCTCTCCAGCCACCTGCCAACCGTA
GAGCTGCCGACATCCTCCTCTGGTGGGAGTGGCCTGCATGGTGCCAGGCTGAGGCCTAGTG
TCAGACAGGGAGCCTGGAATCATAGGGATCCAGGACTCAAAAGTGCTAGAGAATGGCCAT
ATGTCACCATCCATGAAATCTCAAGGGCTTCTGGGTGGAGGGCACAGGGACCTGAACTTAT
GGGTTTTCCCCAAGTCTATTGCTCTCCCAAGTGAGTCTCCCAGATACGAGGCACTGTGCCAG
CATCAGCCTTATCTCCACCACATCTTGTAAAAGGGACTACCCAGGGCCCTGATGAACACCA
TGGTGTGTACAGGAGTAGGGGGTGGAGGCACGGACTCCTGTGAGGTCACAGCCAAGGGAG
CATCATCATGGGTGGGGAGGAGGCAATGGACAGGCTTGAGAACGGGGATGTGGTTGTATTT
GGTTTTCTTTGGTTAGATAAAGTGCTGGGTATAGGATTGAGAGTGGAGTATGAAGACCAGT
TAGGATGGAGGATCAGATTGGAGTTGGGTTAGAGATGGGGTAAAATTGTGCTTCGGATGAG
TTTGGGATTGACACTGTGGAGGTGGTTTGGGATGGCATGGCTTTGGGATGGAAATAGATTT
GTTTTGATGTTGGCTCAGACATCCTTGGGGATTGAACTGGGGATGAAGCTGGGTTTGATTTT
GGAGGTAGAAGACGTGGAAGTAGCTGTCAGATTTGACAGTGGCCATGAGTTTTGTTTGATG
GGGAATCAAACAATGGGGGAAGACATAAGGGTTGGCTTGTTAGGTTAAGTTGCGTTGGGTT
GATGGGGTCGGGGCTGTGTATAATGCAGTTGGATTGGTTTGTATTAAATTGGGTTGGGTCA
GGTTTTGGTTGAGGATGAGTTGAGGATATGCTTGGGGACACCGGATCCATGAGGTTCTCAC
TGGAGTGGAGACAAACTTCCTTTCCAGGATGAATCCGGGGAAGCCTTAATTCACGTGTAGG
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GGAGGTCAGGCCACTGGCTAAGTATATCCTTCCACTCCAGCTCTAAGATGGTCTTAAATTGT
GATTATCTATATCCACCTCTGTCTCCCTCA 
 
antisense (AS1-AS4): 
TCCGGAACACAGATCTGACATGCTCATCTGCTGCGTGGGGTTTACTATCTGCCTTGAATCCT
AAAGTCTGCCCCTGAGGAGTCTGGAATCTGGAATCTATTATCTTTAGTTGAACACCTGCAGT
CTGCGTTCTGCTTTGCAGAGCTGGATTCTTTACCCGTGATCCGTTCTGGCATTTCAACTTCAC
ACAGAATAGGCCACTTCATGGTACTGTTTTCAACCAATCAAGCAAATTAATCGTTAGAGCC
CTTTCTAATTCCTCTAGTTGCAATGTTAAACCCAATATTTCTGTGTAGTGGGTCCATATTAAT
AAATTCAGCCTGATCTAACCTTATATTCCTTCCACCATTATTCCATACCAACCCTTAATATG
CATTCCCACATATATTTCCTGGATTTCTGTCTATATAATGGGCAATCCCGGCTTTGCCAGTTT
CTAGTGACCTAACATCTCTGTGACTCATGTTATTGTACTTTAAAGTGGAAATAATAACAGTT
CCTGTACAGTTTAGGGCTTCCCAAGATGACCCTCCATTGACATCAGTTGAGATTCCAGGAG
AGTCCAAAAGATCATCCTTAAGGTTCAGTCGTTTGCTAGGATGCTCATGGTTGTGGTTTATT
ACAGCAAAAGGATACAGATGAAAATCTGGCAAGGGAGAGGTGAATGAGGCAAAGACAAG
GAGAACTCAAAGTGCGAAGCTTCTAGTTTTCTTTTCCCGGTGACATCGTGGAAAGCACTAG
CATCTCTAAGCAATGATCTGTGACAATATTCACAGTGTATTGCCATCCAGGGAACTCAACT
GAGCCTTGATGTCCAGAGATTTTTGTGTTTTTTTCTGAGACTGAGTCTCGCTCTGTGCCCAG
GCTGGAGTGCAGTGGTGCAACCTTGGCTCACTGCAAGCTCCGCCTCCTGGGTTCACGCCAT
TCTCCTGCCTCAGCCTCCTGAGTAGCTGGGACTACAGGCACCCGCCACCACGCCTGGCTAA
TTTTTTTGTATTTTTAGTAGAGATGGGGTTTCACTGTGTTAGCCAGGATGGTCTCAGTCTCCT
GACCTCGTGATCTGCCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACTG
CGCCTGGCCGATATCCAGAGATTTTTTGGGGGGCTCCATCACACAGACATGTTGACTGTCTT
CATGGTTGACTTTTAGTATCCAGCCCCTCTAGAAATCTAGCTGATATAGTGTGGCTCAAAAC
CTTCAGCACAAATCACACCGTTAGACTATCTGGTGTGGCCCAAACCTTCAGGTGAACAAAG
GCACTCTAAACTGGCAGGATATTCCAAAGCATTAGAGATGACCTCTTGCAAAGAAAAAGA
AATGGAAAAGAAAAAGAAAGAAAGGAAAAAAAAAAAAAAAAAGAGATGACCTCTCAGGC
TCTGAGGGGAAACGCCTGAGGTCTTTGAGCAAGGTCAGTCCTCTGTTGCACAGTCTCCCTC
ACAGGGTCATTGTGACGATCAAATGTGGTCACGTGTATGAGGCACCAGCACATGCCTGGCT
CTGGGGAGTGCCGTGTAAGTGTATGCTTGCACTGCTGAATGGCTGGGATGTGTCAGGGATT
ATCTTCAGCACTTACAGATGCTCATCTCATCCTCACAGCATCACTATGGGATGGGTATTACT
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GGCCTCATTTGATGGAGAAACTGGCTGTGGCTCAGAAAGGGGGGACCACTAGACCAGGGA
CACTCTGGATGCTGGGGACTCCAGAGACCATGACCACTCACCAACTGCAGAGAAATTAATT
GTGGCCTGATGTCCCTGTCCTGGAGAGGGTGGAGGTGGACCTTCACTAACCTCCTACCTTG
ACCCTCTCTTTTAGGGCTCTTTCTGACCTCCACCATGATACTAGGACCCCATTGTATTCTGTA
CCCTCTTGACTCTATGACCCCCACTGCCCACTGCATCCAGCTGGGTCCCCTCCTATCTCTATT
CCCAGCTGGCCAGTGCAGTCTCAGTGCCCACCTGTTTGTCAGTAACTCTGAAGGGGCTGAC
ATTTTACTGACTTGCAAACAAATAAGCTAACTTTCCAGAGTTTTGTGAATGCTGGCAGAGTC
CATGAGACTCCTGAGTCAGAGGCAAAGGCTTTTACTGCTCACAGCTTAGCAGACAGCATGA
GGTTCATGTTCACATTAGTACACCTTGCCCCCCCCAAATCTTGTAGGGTGACCAGAGCAGTC
TAGGTGGATGCTGTGCA 
 
Real time RT-PCR primers: 
KLK3 Forward; GATGAAACAGGCTGTGCCG 
KLK3 Reverse; CCTCACAGCTACCCACTGCA  
KLK3e S1 Forward; TGGGACAACTTGCAAACCTG 
KLK3e S1 Reverse; CCAGAGTAGGTCTGTTTTCAATCCA 
KLK3e S2 Forward; AGAATTGCCTCCCAACACTG 
KLK3e S2 Reverse; GGACCCACTCCTCACTCAAA 
KLK3e S3 Forward; GATGTGGGAATGGCCTAAGA 
KLK3e S3 Reverse; GGATTAGGTGGCAAGATGGA 
KLK3e S4 Forward; AGGGTATCACCAGCCCTTCT 
KLK3e S4 Reverse; GAGGATGTCGGCAGCTCTAC 
KLK3e S5 Forward; GCCAGCATCAGCCTTATCTC 
KLK3e S5 Reverse; TACAACCACATCCCCGTTCT 
KLK3e S6 Forward; TTGTGCTTCGGATGAGTTTG 
KLK3e S6 Reverse; CCATTGTTTGATTCCCCATC 
KLK3e S7 Forward; GGTCAGGTTTTGGTTGAGGA 
KLK3e S7 Reverse; TGAGGGAGACAGAGGTGGAT 
KLK3e AS4 Forward; TCCGGAACACAGATCTGACA 
KLK3e AS4 Reverse; GAACGGATCACGGGTAAAGA 
KLK3e AS3 Forward; AAATCTGGCAAGGGAGAGGT  
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KLK3e AS3 Reverse; GAGTTCCCTGGATGGCAATA  
KLK3e AS2 Forward; GACGATCAAATGTGGTCACG 
KLK3e AS2 Reverse; CTCCATCAAATGAGGCCAGT 
KLK3e AS1 Forward; TTTTGTGAATGCTGGCAGAG 
KLK3e AS1 Reverse; TGCACAGCATCCACCTAGAC 
KLK2 Forward; GCTGCCCATTGCCTAAAGAAG 
KLK2 Reverse; TGGGAAGCTGTGGCTGACA  
KLK15 Forward; TAACTGTGGCGCTTCCCTCATC 
KLK15 Reverse; AGACGTGGTCCGTAGTTGCTCT
KLK4 Forward; GGCACTGGTCATGGAAAACGA 
KLK4 Reverse; TCAAGACTGTGCAGGCCCAGCC 
NKX31 Forward; CGCAGAACGACCAGCTGAGCA 
NKX31 Reverse; CCTGAAGTGTTTTCAGAGTCCAAC 
NKX31e Forward; GCCCAGTTCATTCTTTGGAA 
NKX31e Reverse; CCAAGTCAAAGGGGAATCCT 
TMPRSS2 Forward; CCTGTGTGCCAAGACGACTG  
TMPRSS2 Reverse; TTATAGCCCATGTCCCTGCAG  
FKBP5 Forward; TGCCAAGACCTTCCGAGGCGTC  
FKBP5 Reverse; GGCTTCCGCTCTGCCCAAAGA  
FKBP5e Forward; GCGGTGTCTTTTCGTAGAGG 
FKBP5e Reverse; TAAGGCCCCTTCCTCATTCT 
PLZF Forward; AGCGGGTACTGCGAACTGC 
PLZF Reverse; ATCGCACAAAGTCCCGGCCAG 
PLZFe Forward; AGACCAGGCCAAAATGTCAG 
PLZFe Reverse; TTTGTTTCCCCTCCTCCTCT 
PDE9A Forward; GATCCCAATGTTTGAAACAGTGAC 
PDE9A Reverse; TCCCAAAGTGGCTGCAGC 
GUCY1A3 Forward; AGCAGTGTGGAGAGCTGGAT 
GUCY1A3 Reverse; CTGATCCAGAGTGCAGTCCA 
GAPDH Forward; CCTGTTCGACAGTCAGCCGCATC  
GAPDH Reverse; GGTGACCAGGCGCCCAATACG 
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PCR primers for constructing plasmids: 
KLK2 promoter luc forward; GATCGAGCTCGAGTTCAAGGCTACAGGGAGC  
KLK2 promoter luc reverse; GATCCTCGAGGGGCTTCAGCATAAGAGTCAG  
KLK2 promoter (-407~+143) was subcloned into pGL3 basic using SacI and XhoI 
KLK3e S1_promoter luc; GATCGGATCCGAATTCTGGGACAACTTGCAAACCTGC 
KLK3e S7_ promoter luc; GATCGTCGACTGAGGGAGACAGAGGTGGATA 
KLK3e S7_promoter luc; GATCGTCGACTGGGACAACTTGCAAACCTGC 
KLK3e S1_ promoter luc; GATCGGATCCGAATTCTGAGGGAGACAGAGGTGGATA
KLK3e_S2 promoter luc; GATCGAATTCAGAATTGCCTCCCAACACTGT 
KLK3e_S7 promoter luc; GATCGTCGACTGAGGGAGACAGAGGTGGATA  
Full-length (S1-S7), flipped (S7-S1) and ARE deleted (S2-S7) KLK3e were subcloned into KLK2 
promoter (-407~+143) luc using BamHI+EcoRI and SalI. 
KLK3e_S1; GATCGAATTCTGGGACAACTTGCAAACCTGC 
KLK3e_S7; GATCTCTAGATGAGGGAGACAGAGGTGGATA 
KLK3e_S7; GATCTCTAGATGGGACAACTTGCAAACCTGC 
KLK3e_S1; GATCGAATTCTGAGGGAGACAGAGGTGGATA 
KLK3e_S2; GATCGAATTCAGAATTGCCTCCCAACACTGT 
KLK3e_S7; GATCTCTAGATGAGGGAGACAGAGGTGGATA 
Full-length (S1-S7), flipped (S7-S1) and ARE deleted (S2-S7) KLK3e were subcloned into pcDNA3 
using EcoRI and XbaI. 
KLK3e_AS1; GATCCTCGAGTGCACAGCATCCACCTAGAC 
KLK3e_AS4; GATCGAATTCTCCGGAACACAGATCTGACA 
antisense KLK3e (AS4-AS1) was subcloned into pcDNA3 using EcoRI and XhoI. 
 
ChIP/RIP real-time PCR primers 
KLK3 Enhancer Forward; TGGGACAACTTGCAAACCTG 
KLK3 Enhancer Reverse; CCAGAGTAGGTCTGTTTTCAATCCA 
KLK3 promoter forward; CCTAGATGAAGTCTCCATGAGCTACA 
KLK3 promoter reverse; GGGAGGGAGAGCTAGCACTTG 
KLK2 promoter forward; CTCCAGACTGATCTAGTATG 
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KLK2 promoter reverse; TTGGCACCTAGATGCTGACC 
NKX31 promoter ChIP forward; GCAGATCTGAGTTTGCACCA 
NKX31 promoter ChIP reverse; TGGGACGATCAAGACAAACA 
TMPRSS2 Promoter forward; CGCCCCAGAGTCCCTTAT 
TMPRSS2 Promoter reverse; TAATCTCAGGAGGCGGTGTC 
U1 Forward; ATACTTACCTGGCAGGGGAG 
U1 Reverse; CAGGGGGAAAGCGCGAACGCA 
 
PCR primers for 3C assays: 
Anchor; TCGATTGTCCTTGACAGTAAACA 
A; GGCTCCAGAGGACCATGATT 
B; GGTACCAGCAAACTTGTCCAG 
C; GACGTCATGTAGCTGCGACT 
D; ACCCTTGACCTCCTGGACTT 
E; TGCCCATTGCCTAAAGAAGT 
F; AGATAAGGCCGTGAGCAGAA 
G; CCCCTCGTGGTTAACATCAC 
H; TGGTTCCCACTACATCCACA 
I; GCTGGAGGTGAGTTCTTTGG 
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